Open AccessBRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review
Author(s) -
Liye Wang,
Qianyi Lu,
Kuikui Jiang,
Ruoxi Hong,
Shusen Wang,
Fei Xu
Publication year - 2021
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000520453
Subject(s) - vemurafenib , medicine , oncology , mutation , breast cancer , concomitant , chemotherapy , triple negative breast cancer , paclitaxel , cancer , carboplatin , cancer research , pathology , gene , metastatic melanoma , biology , cisplatin , genetics
Background: The B-Raf proto-oncogene (BRAFV600E) gene mutation has been identified in a variety of malignancies, but no evidence of the efficacy of vemurafenib treatment in BRAFV600E mutant breast cancer (BC) has been reported. Case Presentation: We reported a 60-year-old woman with confirmed triple-negative BC with BRAFV600E mutation. Progression-free survival (PFS) for first-line chemotherapy was 7 months. The patient received vemurafenib and albumin-bound paclitaxel as second-line therapy, exhibiting regression of some pulmonary metastatic lesions with concomitant progression of other lesions, and achieved 4.4 months of PFS. Genetic testing of the progressed pulmonary lesion revealed the BRAFV600E mutation, and acquired new mutations and AR amplification. The patient ultimately died of multiple organ failure and achieved 12 months of overall survival. Conclusions: The BRAFV600E mutation may be a potential prognostic factor and therapeutic target for BC.